Liang Yun, Liao Shenjie, Zhang Xiaoshen
Department of Cardiovascular Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Academician Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Front Cardiovasc Med. 2022 Jul 5;9:940769. doi: 10.3389/fcvm.2022.940769. eCollection 2022.
Cardiovascular diseases (CVDs) continue to be the leading cause of health problems around the world. Because of its unique properties, reactive oxygen species (ROS)-based nanotechnology offers novel solutions to the diagnosis and treatment of CVDs. In order to identify and further promote the development of ROS-based nanotechnology in CVDs, we here provide a bibliometric analysis. 701 eligible articles about the ROS-based nanotechnology for CVD up to May 26th, 2022, were taken from the Web of Science Core Collection database. The VOSviewer was used to analyze annual publications, countries/institutions, funding agencies, journals and research category, and the research hotspots. From the publication of the first article in 2005 to 2021, the output and the number of citations of articles are on the rise. Based on the bibliometric analysis, we found that the current research focuses on the correlation between diagnosis (sensors and), treatment (oxidative stress, inflammation, and drug delivery) and safety (toxicity). Since 2019, research on nanomedicine and drug delivery has become a hotspot. So, more research in chemistry, materials, biology, and medicine is required to further develop and construct ROS-based nanomaterials.
心血管疾病（CVDs）仍然是全球健康问题的主要原因。基于活性氧（ROS）的纳米技术因其独特的性质，为心血管疾病的诊断和治疗提供了新的解决方案。为了识别并进一步推动基于ROS的纳米技术在心血管疾病领域的发展，我们在此进行文献计量分析。截至2022年5月26日，从科学网核心合集数据库中获取了701篇关于基于ROS的纳米技术用于心血管疾病的符合条件的文章。使用VOSviewer分析年度出版物、国家/机构、资助机构、期刊和研究类别以及研究热点。从2005年第一篇文章发表到2021年，文章的产出量和被引次数都在上升。基于文献计量分析，我们发现当前的研究集中在诊断（传感器等）、治疗（氧化应激、炎症和药物递送）与安全性（毒性）之间的关联。自2019年以来，纳米医学和药物递送的研究成为热点。因此，需要化学、材料、生物学和医学等更多领域的研究来进一步开发和构建基于ROS的纳米材料。
